Abstract
We review our experience on Rifaximin in uncomplicated diverticular disease. Our data show that a 2 week treatment induces modifications in the immune system: local mucosal lymphocytes with TLR-4 were increased. In the peripheral blood CD103 cells, which increased before treatment, returned to normal values after Rifaximin.
Keywords: Diverticular disease, rifaximin, mucosal immunity, TLR2, TLR4, T-lymphocytes.
Mini-Reviews in Medicinal Chemistry
Title:Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease
Volume: 16 Issue: 3
Author(s): F. Pandolfi, S. Frosali, L. Petruzziello, E.E. Newton and G. Costamagna
Affiliation:
Keywords: Diverticular disease, rifaximin, mucosal immunity, TLR2, TLR4, T-lymphocytes.
Abstract: We review our experience on Rifaximin in uncomplicated diverticular disease. Our data show that a 2 week treatment induces modifications in the immune system: local mucosal lymphocytes with TLR-4 were increased. In the peripheral blood CD103 cells, which increased before treatment, returned to normal values after Rifaximin.
Export Options
About this article
Cite this article as:
Pandolfi F., Frosali S., Petruzziello L., Newton E.E. and Costamagna G., Central and Mucosal Immunities are Modified by Non Adsorbable Antibiotic Treatment in Uncomplicated Diverticular Disease, Mini-Reviews in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1389557515666150722104035
DOI https://dx.doi.org/10.2174/1389557515666150722104035 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention of Contrast Induced Nephropathy
Current Drug Therapy Editorial: The Biologic Era: A Comprehensive Approach for Inflammatory and Immune-mediated Diseases
Current Pharmaceutical Biotechnology Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?
Current Rheumatology Reviews Application of Radioisotopes in Inflammation
Current Medicinal Chemistry The FRK / RAK-SHB Signaling Cascade: A Versatile Signal- Transduction Pathway that Regulates Cell Survival, Differentiation and Proliferation
Current Molecular Medicine Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Cyclooxygenase-2 Expression, Prostacyclin Production and Endothelial Protection of High-density Lipoprotein
Cardiovascular & Hematological Disorders-Drug Targets Emerging Pathways and Promising Agents with Possible Disease Modifying Effect in Osteoarthritis Treatment
Current Drug Targets The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Generation of Pharmacophore and Atom Based 3D-QSAR Model of Novel Isoquinolin-1-one and Quinazolin-4-one-type Inhibitors of TNFα
Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology Protective Effect of Urate Oxidase on Uric Acid Induced-Monocyte Apoptosis
Current Drug Discovery Technologies Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Mechanisms Involved in the Increased Hemolysis in the Fetus and Newborn
Current Pediatric Reviews The Impact of Omega-3 Fatty Acids on Osteoporosis
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Glucocorticoid-induced Tumor Necrosis Factor Receptor Ligand Aggravates Lipopolysaccharide-induced Inflammation by Down-regulating the Programmed Death Ligand in Kupffer Cells
Current Signal Transduction Therapy Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Hyaluronan: The Jekyll and Hyde Molecule
Inflammation & Allergy - Drug Targets (Discontinued)